FDA Approves Breakthrough Therapy Designation for Hodgkin’s Lymphoma Treatment Keytruda
News
The FDA has granted Merck’s anti-PD-1 therapy Keytruda (pembrolizumab), Breakthrough Therapy Designation (BTD) for the treatment of patients with relapsed or refractory (r/r) classical Hodgkin’s lymphoma (cHL). The FDA previously granted BTD ... Read more